{"id":15814,"date":"2020-08-19T16:45:10","date_gmt":"2020-08-19T14:45:10","guid":{"rendered":"https:\/\/cri1149.fr\/?post_type=publications&#038;p=15814"},"modified":"2025-09-11T16:48:01","modified_gmt":"2025-09-11T14:48:01","slug":"eliminating-hepatitis-c-within-low-income-countries-the-need-to-cure-genotypes-4-5-6","status":"publish","type":"publication","link":"https:\/\/cri1149.fr\/en\/publication\/eliminating-hepatitis-c-within-low-income-countries-the-need-to-cure-genotypes-4-5-6\/","title":{"rendered":"Eliminating hepatitis C within low-income countries &#8211; The need to cure genotypes 4, 5, 6"},"content":{"rendered":"","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false,"_EventAllDay":false,"_EventTimezone":"","_EventStartDate":"","_EventEndDate":"","_EventStartDateUTC":"","_EventEndDateUTC":"","_EventShowMap":false,"_EventShowMapLink":false,"_EventURL":"","_EventCost":"","_EventCostDescription":"","_EventCurrencySymbol":"","_EventCurrencyCode":"","_EventCurrencyPosition":"","_EventDateTimeSeparator":"","_EventTimeRangeSeparator":"","_EventOrganizerID":[],"_EventVenueID":[],"_OrganizerEmail":"","_OrganizerPhone":"","_OrganizerWebsite":"","_VenueAddress":"","_VenueCity":"","_VenueCountry":"","_VenueProvince":"","_VenueState":"","_VenueZip":"","_VenuePhone":"","_VenueURL":"","_VenueStateProvince":"","_VenueLat":"","_VenueLng":"","_VenueShowMap":false,"_VenueShowMapLink":false},"category_publication":[],"class_list":["post-15814","publication","type-publication","status-publish","hentry"],"acf":{"numero_de_publication":"J Hepatol","date_de_publication":"20180401","numero_doi":"","equipe":[130],"auteurs-liste":[{"texte_libre":false,"auteur-lien":13023,"auteur-text":[]},{"texte_libre":true,"auteur-lien":null,"auteur-text":"[:fr]Tarek Hassanein[:]"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"[:fr]Imam Waked[:]"},{"texte_libre":false,"auteur-lien":13112,"auteur-text":[]},{"texte_libre":true,"auteur-lien":null,"auteur-text":"[:fr]Geoffrey Dusheiko[:]"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"[:fr]Edward Gane [:]"}],"auteurs-manuel":"","liens_externes":null,"liens":[{"lien":"https:\/\/pubmed.ncbi.nlm.nih.gov\/29229584\/"}],"paragraphe":"<h2 class=\"title\" style=\"text-align: justify;\">Abstract<\/h2>\r\n<div id=\"enc-abstract\" class=\"abstract-content selected\">\r\n<p style=\"text-align: justify;\">Around 70 to 100 million people are chronically infected with HCV worldwide. HCV antiviral drug development has revolutionised the treatment of HCV, with several direct-acting antiviral agents offering patients the chance of cure after only 8-12 weeks of treatment. Drug development was initially focussed on HCV genotype 1 (GT1) infection, since this was the most prevalent worldwide, although clinical trials included all genotypes prevalent in the US and Europe. Because the earliest in vitro assays utilised the GT1b and 2 replicons, the initial classes of direct-acting antivirals (protease inhibitors, non-nucleotide polymerase inhibitors) were GT1-specific, albeit they had an effect on other less prevalent genotypes. Epidemiological data has shown the regional importance of other HCV genotypes. More than 50% of all HCV infections around the globe are not with GT1. The prevalence of HCV genotype 4 (GT4), 5 (GT5), and 6 (GT6) is increasing in North America and Europe due to migration from the Middle East, Africa and South-East Asia. With the successful development of the multi and pan-genotypic non-structural protein 5A inhibitors, second generation protease inhibitors and nucleotide non-structural protein 5B inhibitors comes a unique opportunity to achieve global HCV elimination. The goal of this review is to summarise the available information pertaining to GT4, GT5 and GT6, with a specific focus on direct-acting antiviral agents.<\/p>\r\n<\/div>","paragraphe_en":"<h2 class=\"title\" style=\"text-align: justify;\">Abstract<\/h2>\r\n<div id=\"enc-abstract\" class=\"abstract-content selected\">\r\n<p style=\"text-align: justify;\">Around 70 to 100 million people are chronically infected with HCV worldwide. HCV antiviral drug development has revolutionised the treatment of HCV, with several direct-acting antiviral agents offering patients the chance of cure after only 8-12 weeks of treatment. Drug development was initially focussed on HCV genotype 1 (GT1) infection, since this was the most prevalent worldwide, although clinical trials included all genotypes prevalent in the US and Europe. Because the earliest in vitro assays utilised the GT1b and 2 replicons, the initial classes of direct-acting antivirals (protease inhibitors, non-nucleotide polymerase inhibitors) were GT1-specific, albeit they had an effect on other less prevalent genotypes. Epidemiological data has shown the regional importance of other HCV genotypes. More than 50% of all HCV infections around the globe are not with GT1. The prevalence of HCV genotype 4 (GT4), 5 (GT5), and 6 (GT6) is increasing in North America and Europe due to migration from the Middle East, Africa and South-East Asia. With the successful development of the multi and pan-genotypic non-structural protein 5A inhibitors, second generation protease inhibitors and nucleotide non-structural protein 5B inhibitors comes a unique opportunity to achieve global HCV elimination. The goal of this review is to summarise the available information pertaining to GT4, GT5 and GT6, with a specific focus on direct-acting antiviral agents.<\/p>\r\n<\/div>","documents":null},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Eliminating hepatitis C within low-income countries - The need to cure genotypes 4, 5, 6 - CRI<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cri1149.fr\/publication\/eliminating-hepatitis-c-within-low-income-countries-the-need-to-cure-genotypes-4-5-6\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eliminating hepatitis C within low-income countries - The need to cure genotypes 4, 5, 6 - CRI\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cri1149.fr\/publication\/eliminating-hepatitis-c-within-low-income-countries-the-need-to-cure-genotypes-4-5-6\/\" \/>\n<meta property=\"og:site_name\" content=\"CRI\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/CRI-Centre-de-recherche-sur-linflammation-100116118884153\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-11T14:48:01+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cri1149.fr\/publication\/eliminating-hepatitis-c-within-low-income-countries-the-need-to-cure-genotypes-4-5-6\/\",\"url\":\"https:\/\/cri1149.fr\/publication\/eliminating-hepatitis-c-within-low-income-countries-the-need-to-cure-genotypes-4-5-6\/\",\"name\":\"Eliminating hepatitis C within low-income countries - The need to cure genotypes 4, 5, 6 - CRI\",\"isPartOf\":{\"@id\":\"https:\/\/cri1149.fr\/#website\"},\"datePublished\":\"2020-08-19T14:45:10+00:00\",\"dateModified\":\"2025-09-11T14:48:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cri1149.fr\/publication\/eliminating-hepatitis-c-within-low-income-countries-the-need-to-cure-genotypes-4-5-6\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cri1149.fr\/publication\/eliminating-hepatitis-c-within-low-income-countries-the-need-to-cure-genotypes-4-5-6\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cri1149.fr\/publication\/eliminating-hepatitis-c-within-low-income-countries-the-need-to-cure-genotypes-4-5-6\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/cri1149.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publications\",\"item\":\"https:\/\/cri1149.fr\/publications\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Eliminating hepatitis C within low-income countries &#8211; The need to cure genotypes 4, 5, 6\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cri1149.fr\/#website\",\"url\":\"https:\/\/cri1149.fr\/\",\"name\":\"CRI - Centre de Recherche sur l'Inflammation\",\"description\":\"Centre de Recherche sur l&#039;Inflammation\",\"publisher\":{\"@id\":\"https:\/\/cri1149.fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cri1149.fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cri1149.fr\/#organization\",\"name\":\"CRI1149\",\"url\":\"https:\/\/cri1149.fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cri1149.fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cri1149.fr\/wp-content\/uploads\/2014\/11\/8.4.2014-logo-CRI.jpg\",\"contentUrl\":\"https:\/\/cri1149.fr\/wp-content\/uploads\/2014\/11\/8.4.2014-logo-CRI.jpg\",\"width\":215,\"height\":176,\"caption\":\"CRI1149\"},\"image\":{\"@id\":\"https:\/\/cri1149.fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/CRI-Centre-de-recherche-sur-linflammation-100116118884153\",\"https:\/\/www.linkedin.com\/company\/cri-centre-de-recherche-sur-l-inflammation\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eliminating hepatitis C within low-income countries - The need to cure genotypes 4, 5, 6 - CRI","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cri1149.fr\/publication\/eliminating-hepatitis-c-within-low-income-countries-the-need-to-cure-genotypes-4-5-6\/","og_locale":"en_US","og_type":"article","og_title":"Eliminating hepatitis C within low-income countries - The need to cure genotypes 4, 5, 6 - CRI","og_url":"https:\/\/cri1149.fr\/publication\/eliminating-hepatitis-c-within-low-income-countries-the-need-to-cure-genotypes-4-5-6\/","og_site_name":"CRI","article_publisher":"https:\/\/www.facebook.com\/CRI-Centre-de-recherche-sur-linflammation-100116118884153","article_modified_time":"2025-09-11T14:48:01+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cri1149.fr\/publication\/eliminating-hepatitis-c-within-low-income-countries-the-need-to-cure-genotypes-4-5-6\/","url":"https:\/\/cri1149.fr\/publication\/eliminating-hepatitis-c-within-low-income-countries-the-need-to-cure-genotypes-4-5-6\/","name":"Eliminating hepatitis C within low-income countries - The need to cure genotypes 4, 5, 6 - CRI","isPartOf":{"@id":"https:\/\/cri1149.fr\/#website"},"datePublished":"2020-08-19T14:45:10+00:00","dateModified":"2025-09-11T14:48:01+00:00","breadcrumb":{"@id":"https:\/\/cri1149.fr\/publication\/eliminating-hepatitis-c-within-low-income-countries-the-need-to-cure-genotypes-4-5-6\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cri1149.fr\/publication\/eliminating-hepatitis-c-within-low-income-countries-the-need-to-cure-genotypes-4-5-6\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/cri1149.fr\/publication\/eliminating-hepatitis-c-within-low-income-countries-the-need-to-cure-genotypes-4-5-6\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/cri1149.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Publications","item":"https:\/\/cri1149.fr\/publications\/"},{"@type":"ListItem","position":3,"name":"Eliminating hepatitis C within low-income countries &#8211; The need to cure genotypes 4, 5, 6"}]},{"@type":"WebSite","@id":"https:\/\/cri1149.fr\/#website","url":"https:\/\/cri1149.fr\/","name":"CRI - Centre de Recherche sur l'Inflammation","description":"Centre de Recherche sur l&#039;Inflammation","publisher":{"@id":"https:\/\/cri1149.fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cri1149.fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cri1149.fr\/#organization","name":"CRI1149","url":"https:\/\/cri1149.fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cri1149.fr\/#\/schema\/logo\/image\/","url":"https:\/\/cri1149.fr\/wp-content\/uploads\/2014\/11\/8.4.2014-logo-CRI.jpg","contentUrl":"https:\/\/cri1149.fr\/wp-content\/uploads\/2014\/11\/8.4.2014-logo-CRI.jpg","width":215,"height":176,"caption":"CRI1149"},"image":{"@id":"https:\/\/cri1149.fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/CRI-Centre-de-recherche-sur-linflammation-100116118884153","https:\/\/www.linkedin.com\/company\/cri-centre-de-recherche-sur-l-inflammation\/"]}]}},"_links":{"self":[{"href":"https:\/\/cri1149.fr\/en\/wp-json\/wp\/v2\/publication\/15814","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cri1149.fr\/en\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/cri1149.fr\/en\/wp-json\/wp\/v2\/types\/publication"}],"acf:term":[{"embeddable":true,"taxonomy":"equipes","href":"https:\/\/cri1149.fr\/en\/wp-json\/wp\/v2\/equipes\/130"}],"wp:attachment":[{"href":"https:\/\/cri1149.fr\/en\/wp-json\/wp\/v2\/media?parent=15814"}],"wp:term":[{"taxonomy":"category_publication","embeddable":true,"href":"https:\/\/cri1149.fr\/en\/wp-json\/wp\/v2\/category_publication?post=15814"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}